Immunovant, Inc.(IMVT)

$44.37—

Chart

Immunovant, Inc.(IMVT)

NASDAQ

$44.37—

Chart Studio

IMVT(IMVT)

IMVT

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.73

Nov 9, 2026 · Reports before open

Revenue Estimate

$7M

FY2030E EPS$0.14

FY2031E EPS$2.78

Analyst Sentiment

Wall St. Consensus

Buy

23 analysts·High coverage

Score

18 Buy (78%)4 Hold (17%)1 Sell (5%)

Rating Breakdown

Strong Buy

00%

Buy

1878%

Hold

417%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$40.00

-9.8%

Consensus

$40.00

-9.8%

Bull

$40.00

-9.8%

12-Month Target Range23 analysts

$40.00$40.00$40.00

Current $44.37Consensus

Current Price

$44.37

Above Consensus

$4.37

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-36.66%

EPS—

FY2028

Rev+605.03%

EPS—

FY2029

Rev+760.77%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2027E	FY2028E	FY2029E	FY2030E	FY2031E
Revenue Avg	$7M	$47M	$403M	$921M	$1.71B
Low	$7M	$47M	$385M	$921M	$1.71B
High	$7M	$47M	$422M	$921M	$1.71B
EBITDA Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
EBIT Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
Net Income Avg	$-526M	$-593M	$-369M	$26M	$507M
Low	$-582M	$-623M	$-620M	$26M	$507M
High	$-470M	$-436M	$-6M	$26M	$507M
EPS Avg	$-2.93	$-2.89	$-1.87	$0.14	$2.78
Low	$-3.19	$-3.42	$-3.40	$0.14	$2.78
High	$-2.57	$-2.39	$-0.04	$0.14	$2.78
Analysts (Rev / EPS)	9 / 9	9 / 8	11 / 11	6 / 5	6 / 7

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$7M	$7M	$14M	$7M	$7M	$7M	$43M	$7M
Low	$7M	$7M	$14M	$7M	$7M	$7M	$43M	$7M
High	$7M	$7M	$14M	$7M	$7M	$7M	$43M	$7M
EBITDA Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
Net Income Avg	$-151M	$-149M	$-150M	$-148M	$-149M	$-155M	$-155M	$-123M
Low	$-164M	$-166M	$-150M	$-148M	$-149M	$-155M	$-155M	$-123M
High	$-130M	$-129M	$-150M	$-148M	$-149M	$-155M	$-155M	$-123M
EPS Avg	$-0.74	$-0.73	$-0.73	$-0.72	$-0.73	$-0.76	$-0.75	$-0.60
Low	$-0.80	$-0.81	$-0.73	$-0.72	$-0.73	$-0.76	$-0.75	$-0.60
High	$-0.63	$-0.63	$-0.73	$-0.72	$-0.73	$-0.76	$-0.75	$-0.60
Analysts (Rev / EPS)	1 / 4	1 / 4	1 / 1	1 / 1	1 / 1	1 / 1	1 / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

May 21, 2026H.C. Wainwright

Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright

Target:$40.00

+12.5%from $35.56

Jan 6, 2026Wolfe Research

Immunovant upgraded to Outperform at Wolfe on improving Graves' perception

Target:$50.00

+100.2%from $24.97

Dec 18, 2025Guggenheim

Immunovant price target lowered to $41 from $44 at Guggenheim

Target:$41.00

+56.1%from $26.27

Oct 14, 2025Truist Financial

Immunovant initiated with a Hold at Truist

Target:$16.00

-7.8%from $17.35

Sep 10, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)

Target:$51.00

+68.9%from $30.20

Jun 3, 2024Oppenheimer

Immunovant price target lowered to $46 from $50 at Oppenheimer

Target:$46.00

+81.2%from $25.39

May 30, 2024Guggenheim

Immunovant (IMVT) PT Lowered to $48 at Guggenheim

Target:$48.00

+81.7%from $26.41

May 30, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)

Target:$57.00

+104.8%from $27.83

Mar 13, 2024Goldman Sachs

Goldman Sachs Starts Immunovant (IMVT) at Buy

Target:$50.00

+57.1%from $31.82

Sep 26, 2022UBS

Immunovant downgraded to Neutral from Buy at UBS

Target:$5.00

+2.5%from $4.88

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance